News

Under the agreement, New WuXi Life will acquire WuXi PharmaTech for cash consideration equal to $5.75 per ordinary share and $46 per American depositary share (ADS). Each ADS

As per the agreement, which comprises an initial cash license fee and a per-unit royalty of the greater of $50 or 20% of the gross purchase price paid

The open-label, multicenter, single-arm Phase II study BIRCH observed that atezolizumab shrank tumors in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expressed

In either the single or multiple ascending dose arms of the double-blind, randomized clinical trial, CAT-2054 was well-tolerated with no serious adverse events (AEs) observed. In the multiple

Plegridy is a new molecular entity, resulting from the application of pegylation technology and it offers a new combination of demonstrated efficacy, a favourable safety profile consistent with

As part of the deal, SIFI will be responsible for managing all promotion, marketing and commercial activities in those locations for Iluvien, Alimera’s sustained release intravitreal injection to

The randomized, parallel-group, double-blind, placebo-controlled Kinect 3 trial includes around 240 subjects with moderate to severe tardive dyskinesia and an underlying diagnosis of mood disorder, schizophrenia or schizoaffective

As part of the deal, Janssen will secure rights to develop and commercialize ADC-1013, an agonistic fully human monoclonal antibody, that targets CD40, an immuno-stimulatory receptor found on

As part of the three-year deal, several collaborative studies will be conducted in tumor types such as gastroesophageal adenocarcinoma, pancreatic adenocarcinoma and hepatocellular carcinoma. Under the deal, the